Stocks and Investing Stocks and Investing
Thu, August 8, 2024

Brian Abrahams Maintained (SRPT) at Buy with Decreased Target to $181 on, Aug 8th, 2024


Published on 2024-10-28 13:24:15 - WOPRAI, Brian Abrahams
  Print publication without navigation


Brian Abrahams of RBC Capital, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Decreased Target from $182 to $181 on, Aug 8th, 2024.

Brian has made no other calls on SRPT in the last 4 months.



There are 9 other peers that have a rating on SRPT. Out of the 9 peers that are also analyzing SRPT, 0 agree with Brian's Rating of Hold.



These are the ratings of the 9 analyists that currently disagree with Brian


  • Gil Blum of "Needham" Reiterated at Strong Buy and Held Target at $235 on, Thursday, June 27th, 2024
  • Kostas Biliouris of "BMO Capital" Maintained at Buy with Increased Target to $200 on, Monday, June 24th, 2024
  • Mani Foroohar of "Leerink Partners" Maintained at Buy with Increased Target to $230 on, Monday, June 24th, 2024
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $200 on, Monday, June 24th, 2024
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $213 on, Friday, June 21st, 2024
  • Brian Skorney of "Baird" Maintained at Buy with Increased Target to $200 on, Friday, June 21st, 2024
  • Uy Ear of "Mizuho" Maintained at Strong Buy with Increased Target to $179 on, Friday, May 17th, 2024
  • Hartaj Singh of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $180 on, Tuesday, May 14th, 2024
  • Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $175 on, Friday, May 3rd, 2024
Contributing Sources